Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic disease characterized by the destruction of the small intrahepatic bile ducts, which can progress to liver cirrhosis. The gold standard in the treatment of PBC is ursodeoxycholic acid (UDCA), which is indicated in all patients with PBC because it improves not only biochemical parameters but also patients' survival. An important milestone in the identification of patients at risk is the assessment of biochemical response to UDCA. Patients who respond to treatment have a lower incidence of hepatic events and better prognosis than patients who do not. Several scoring systems can be used to assess the response and identify non-responders who will benefit from second-line treatment. Obeticholic acid (OCA) is currently the only approved second-line treatment for PBC, which is effective for non-responders to UDCA therapy or patients, who have not tolerated UDCA therapy. However, OCA is contraindicated in advanced liver cirrhosis and portal hypertension. Moreover, pruritus may be a limiting factor for the administration of OCA. Fibrates have shown promising data supporting their use in non-responders to UDCA because they improve the biochemical parameters and elastographic findings and have possible antipruritic effects. Therefore, the idea of a triple treatment seems interesting. Clinical research is focusing on several other groups of drugs: peroxisome proliferator-activated receptor (PPAR) δ- and α/δ agonists, non-steroidal farnesoid X receptor agonists, fibroblast growth factor 19 modulators, and inhibitors of nicotinamide adenine dinucleotide phosphate oxidase 1 and 4.

2nd Department of Internal Medicine Faculty of Medicine and Louis Pasteur University Hospital Pavol Jozef Safarik University Kosice Slovakia

2nd Department of Internal Medicine Faculty of Medicine and Louis Pasteur University Hospital Pavol Jozef Safarik University Trieda SNP 1 Kosice 040 11 Slovakia

Department of Hepatogastroenterology Institute for Clinical and Experimental Medicine Prague 4 Czech Republic

Erratum v

Therap Adv Gastroenterol. 2024 Aug 31;17:17562848241277276. doi: 10.1177/17562848241277276. PubMed

Zobrazit více v PubMed

European Association for the Study of the Liver. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017; 67: 145–172. PubMed

Lindor KD, Bowlus CL, Boyer J, et al.. Primary biliary cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology 2019; 69: 394–419. PubMed

Lu M, Zhou Y, Haller IV, et al.. Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment. Clin Gastroenterol Hepatol 2018; 16: 1342–1350.e1. PubMed

Drazilova S, Babinska I, Gazda J, et al.. Epidemiology and clinical course of primary biliary cholangitis in Eastern Slovakia. Int J Public Health 2020; 65: 683–691. PubMed

Ratziu V. Non-pharmacological interventions in non-alcoholic fatty liver disease patients. Liver Int 2017; 37(Suppl. 1): 90–96. PubMed

French JA, Gow P, Simpson-Yap S, et al.. Alcohol intake is associated with a decreased risk of developing primary biliary cholangitis. World J Hepatol 2022; 14: 1747–1756. PubMed PMC

Angulo P, Lindor KD. Management of primary biliary cirrhosis and autoimmune cholangitis. Clin Liver Dis 1998; 2: 333–351, ix. PubMed

Poupon R, Chretien Y, Poupon RE, et al.. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987; 1: 834–836. PubMed

Ishizaki K, Imada T, Tsurufuji M. Hepatoprotective bile acid ‘ursodeoxycholic acid (UDCA)’ property and difference as bile acids. Hepatol Res 2005; 33: 174–177. PubMed

Pinyopornpanish K. Ursodeoxycholic acid in liver cirrhosis: an evidence-based review. In: Xingshun Q, Yongping Y. (eds.) Pharmacotherapy for liver cirrhosis and its complications. Singapore: Springer, 2022, pp.69–80.

Corpechot C, Carrat F, Bonnand AM, et al.. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000; 32: 1196–1199. PubMed

Simental-Mendia LE, Simental-Mendia M, Sanchez-Garcia A, et al.. Impact of ursodeoxycholic acid on circulating lipid concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Lipids Health Dis 2019; 18: 88. PubMed PMC

Hempfling W, Dilger K, Beuers U. Systematic review: ursodeoxycholic acid – adverse effects and drug interactions. Aliment Pharmacol Ther 2003; 18: 963–972. PubMed

Gong Y, Huang Z, Christensen E, et al.. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol 2007; 102: 1799–1807. PubMed

Rudic JS, Poropat G, Krstic MN, et al.. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2012; 12: CD000551. PubMed PMC

Harms MH, van Buuren HR, Corpechot C, et al.. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J Hepatol 2019; 71: 357–365. PubMed

Gatselis NK, Goet JC, Zachou K, et al.. Factors associated with progression and outcomes of early stage primary biliary cholangitis. Clin Gastroenterol Hepatol 2020; 18: 684–692.e6. PubMed

Angulo P, Batts KP, Therneau TM, et al.. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999; 29: 644–647. PubMed

Degott C, Zafrani ES, Callard P, et al.. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology 1999; 29: 1007–1012. PubMed

Kumagi T, Guindi M, Fischer SE, et al.. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 2010; 105: 2186–2194. PubMed

Dražilová S, Gurtler Ľ, Skladaný Ľ, et al.. Primárna biliárna cholangoitída – odporúčania pre prax. Lekársky obzor 2020; 69: 21–28.

Angulo P, Lindor KD, Therneau TM, et al.. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver 1999; 19: 115–121. PubMed

Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 2006; 130: 715–720. PubMed

Corpechot C, Abenavoli L, Rabahi N, et al.. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008; 48: 871–877. PubMed

Corpechot C, Chazouilleres O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 2011; 55: 1361–1367. PubMed

Kuiper EM, Hansen BE, de Vries RA, et al.. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009; 136: 1281–1287. PubMed

Azemoto N, Abe M, Murata Y, et al.. Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis. J Gastroenterol 2009; 44: 630–634. PubMed

Gazda J, Drazilova S, Janicko M, et al.. Prognostic factors in primary biliary cholangitis: a retrospective study of joint slovak and croatian cohort of 249 patients. J Pers Med 2021; 11: 495. PubMed PMC

Yang C, Guo G, Li B, et al.. Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion. Hepatol Int 2023; 17: 237–248. PubMed PMC

Murillo Perez CF, Harms MH, Lindor KD, et al.. Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase. Am J Gastroenterol 2020; 115: 1066–1074. PubMed

Carbone M, Sharp SJ, Flack S, et al.. The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology 2016; 63: 930–950. PubMed PMC

Lammers WJ, Hirschfield GM, Corpechot C, et al.. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology 2015; 149: 1804–1812.e4. PubMed

Carbone M, Nardi A, Flack S, et al.. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. Lancet Gastroenterol Hepatol 2018; 3: 626–634. PubMed PMC

Cancado GGL, Braga MH, Ferraz MLG, et al.. Clinical features and treatment outcomes of primary biliary cholangitis in a highly admixed population. Ann Hepatol 2022; 27: 100546. PubMed

Cortez-Pinto H, Liberal R, Lopes S, et al.. Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease. United Eur Gastroenterol J 2021; 9: 699–706. PubMed PMC

Wen M, Men R, Fan X, et al.. Worse response to ursodeoxycholic acid in primary biliary cholangitis patients with autoimmune hepatitis features. Dig Dis 2021; 39: 366–374. PubMed

Yehezkel E, Israel I, Houri I, et al.. Real-world management of patients with primary biliary cholangitis – a retrospective study from a Tertiary Medical Center in Israel. J Clin Med 2021; 10: 4551. PubMed PMC

Lin L, Piao M, Jiang X, et al.. Does neutrophil-to-lymphocyte ratio predict 1-year mortality in patients with primary biliary cholangitis? Results from a retrospective study with validation cohort. BMJ Open 2017; 7: e015304. PubMed PMC

Yamashita Y, Umemura T, Kimura T, et al.. Prognostic utility of albumin-bilirubin grade in Japanese patients with primary biliary cholangitis. JHEP Rep 2023; 5: 100662. PubMed PMC

Chang JI, Kim JH, Sinn DH, et al.. Clinical outcomes and validation of ursodeoxycholic acid response scores in patients with Korean primary biliary cholangitis: a multicenter cohort study. Gut Liver 2023; 17: 620–628. PubMed PMC

Gazda J, Janicko M, Drazilova S, et al.. External validation of UDCA response score in slovak and croatian patients with primary biliary cholangitis. Can J Gastroenterol Hepatol 2021; 2021: 9928065. PubMed PMC

Li J, Lu M, Zhou Y, et al.. Dynamic risk prediction of response to ursodeoxycholic acid among patients with primary biliary cholangitis in the USA. Dig Dis Sci 2022; 67: 4170–4180. PubMed

Kawata K, Joshita S, Shimoda S, et al.. The ursodeoxycholic acid response score predicts pathological features in primary biliary cholangitis. Hepatol Res 2021; 51: 80–89. PubMed

Lammers WJ, Kowdley KV, van Buuren HR. Predicting outcome in primary biliary cirrhosis. Ann Hepatol 2014; 13: 316–326. PubMed

Corpechot C, Carrat F, Poujol-Robert A, et al.. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology 2012; 56: 198–208. PubMed

Murillo Perez CF, Hirschfield GM, Corpechot C, et al.. Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. Aliment Pharmacol Ther 2019; 50: 1127–1136. PubMed

Yu K, Li P, Xu T, et al.. Decreased infiltration of CD4(+) Th1 cells indicates a good response to ursodeoxycholic acid (UDCA) in primary biliary cholangitis. Pathol Res Pract 2021; 217: 153291. PubMed

Bossen L, Lau TS, Nielsen MB, et al.. The association between soluble CD163, disease severity, and ursodiol treatment in patients with primary biliary cholangitis. Hepatol Commun 2023; 7: e0068. PubMed PMC

Wang Q, Wang Y, Qiao W, et al.. The effect of serum IL-2 levels on the prognosis of primary biliary cholangitis-related liver failure and the preliminary exploration of its mechanism. Front Immunol 2022; 13: 995223. PubMed PMC

Barron-Millar B, Ogle L, Mells G, et al.. The serum proteome and ursodeoxycholic acid response in primary biliary cholangitis. Hepatology 2021; 74: 3269–3283. PubMed

Furukawa M, Moriya K, Nakayama J, et al.. Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis. Hepatol Res 2020; 50: 840–852. PubMed

Juliusson G, Imam M, Bjornsson ES, et al.. Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis. Scand J Gastroenterol 2016; 51: 745–752. PubMed

Chen Q, Zhong R, Dong K, et al.. The prognostic value of antibodies to gp210 among patients with primary biliary cholangitis in Northeast China. Dig Liver Dis 2022; 54: 1094–1100. PubMed

Abdulkarim M, Zenouzi R, Sebode M, et al.. Sex differences in clinical presentation and prognosis in patients with primary biliary cholangitis. Scand J Gastroenterol 2019; 54: 1391–1396. PubMed

Marschall HU, Henriksson I, Lindberg S, et al.. Incidence, prevalence, and outcome of primary biliary cholangitis in a nationwide Swedish population-based cohort. Sci Rep 2019; 9: 11525. PubMed PMC

Gazda J, Drazilova S, Gazda M, et al.. Treatment response to ursodeoxycholic acid in primary biliary cholangitis: a systematic review and meta-analysis. Dig Liver Dis 2023; 55: 1318–1327. PubMed

Levy C, Manns M, Hirschfield G. New treatment paradigms in primary biliary cholangitis. Clin Gastroenterol Hepatol 2023; 21: 2076–2087. PubMed

Beuers U, Trauner M, Jansen P, et al.. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol 2015; 62: S25–S37. PubMed

Pellicciari R, Costantino G, Camaioni E, et al.. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. J Med Chem 2004; 47: 4559–4569. PubMed

Floreani A, Gabbia D, De Martin S. Obeticholic acid for primary biliary cholangitis. Biomedicines 2022; 10: 2464. PubMed PMC

Verbeke L, Mannaerts I, Schierwagen R, et al.. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Sci Rep 2016; 6: 33453. PubMed PMC

Chapman RW, Lynch KD. Obeticholic acid – a new therapy in PBC and NASH. Br Med Bull 2020; 133: 95–104. PubMed

Keshvani C, Kopel J, Goyal H. Obeticholic acid – a pharmacological and clinical review. Future Pharmacol 2023; 3: 238–251.

Nevens F, Andreone P, Mazzella G, et al.. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 2016; 375: 631–643. PubMed

Trauner M, Nevens F, Shiffman ML, et al.. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. Lancet Gastroenterol Hepatol 2019; 4: 445–453. PubMed

Bowlus CL, Pockros PJ, Kremer AE, et al.. Long-term obeticholic acid therapy improves histological endpoints in patients with primary biliary cholangitis. Clin Gastroenterol Hepatol 2020; 18: 1170–1178.e6. PubMed

Murillo Perez CF, Fisher H, Hiu S, et al.. Greater transplant-free survival in patients receiving obeticholic acid for primary biliary cholangitis in a clinical trial setting compared to real-world external controls. Gastroenterology 2022; 163: 1630–1642.e3. PubMed

Hirschfield GM, Mason A, Luketic V, et al.. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 2015; 148: 751–761.e8. PubMed

Kowdley KV, Luketic V, Chapman R, et al.. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology 2018; 67: 1890–1902. PubMed PMC

Gao Y, Li L, Li B, et al.. Response rate and impact on lipid profiles of obeticholic acid treatment for patients with primary biliary cholangitis: a meta-analysis. Can J Gastroenterol Hepatol 2021; 2021: 8829510. PubMed PMC

Roberts SB, Ismail M, Kanagalingam G, et al.. Real-world effectiveness of obeticholic acid in patients with primary biliary cholangitis. Hepatol Commun 2020; 4: 1332–1345. PubMed PMC

Gomez E, Garcia Buey L, Molina E, et al.. Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid. Aliment Pharmacol Ther 2021; 53: 519–530. PubMed

D’Amato D, De Vincentis A, Malinverno F, et al.. Real-world experience with obeticholic acid in patients with primary biliary cholangitis. JHEP Rep 2021; 3: 100248. PubMed PMC

De Vincentis A, D’Amato D, Cristoferi L, et al.. Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid. Liver Int 2022; 42: 2453–2465. PubMed PMC

Londono MC, Diaz-Gonzalez A. Predicting liver-related serious adverse events in patients with primary biliary cholangitis-related cirrhosis treated with obeticholic acid. Liver Int 2022; 42: 2356–2359. PubMed

Lindor KD, Bowlus CL, Boyer J, et al.. Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases. Hepatology 2022; 75: 1012–1013. PubMed

Ng CH, Tang ASP, Xiao J, et al.. Safety and tolerability of obeticholic acid in chronic liver disease: a pooled analysis of 1878 individuals. Hepatol Commun 2023; 7: e0005. PubMed PMC

Levy C. Fibrates for primary biliary cholangitis: what’s all the hype? Ann Hepatol 2017; 16: 704–706. PubMed

Corpechot C, Chazouilleres O, Rousseau A, et al.. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med 2018; 378: 2171–2181. PubMed

Khakoo NS, Sultan S, Reynolds JM, et al.. Efficacy and safety of bezafibrate alone or in combination with ursodeoxycholic acid in primary biliary cholangitis: systematic review and meta-analysis. Dig Dis Sci 2023; 68: 1559–1573. PubMed

Hosonuma K, Sato K, Yamazaki Y, et al.. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. Am J Gastroenterol 2015; 110: 423–431. PubMed

Iwasaki S, Ohira H, Nishiguchi S, et al.. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study. Hepatol Res 2008; 38: 557–564. PubMed

Itakura J, Izumi N, Nishimura Y, et al.. Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis. Hepatol Res 2004; 29: 216–222. PubMed

Kanda T, Yokosuka O, Imazeki F, et al.. Bezafibrate treatment: a new medical approach for PBC patients? J Gastroenterol 2003; 38: 573–578. PubMed

Nakai S, Masaki T, Kurokohchi K, et al.. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. Am J Gastroenterol 2000; 95: 326–327. PubMed

Takano K, Saeki C, Oikawa T, et al.. IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate. J Gastroenterol Hepatol 2020; 35: 663–672. PubMed

Tanaka A, Hirohara J, Nakano T, et al.. Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis. J Hepatol 2021; 75: 565–571. PubMed

Li C, Zheng K, Chen Y, et al.. A randomized, controlled trial on fenofibrate in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid. Ther Adv Chronic Dis 2022; 13: 20406223221114198. PubMed PMC

Dohmen K, Tanaka H, Haruno M. Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis. Fukuoka Igaku Zasshi 2013; 104: 350–361. PubMed

Liu Y, Guo G, Zheng L, et al.. Effectiveness of fenofibrate in treatment-naive patients with primary biliary cholangitis: a randomized clinical trial. Am J Gastroenterol 2023; 118: 1973–1979. PubMed

Zhang H, Li S, Feng Y, et al.. Efficacy of fibrates in the treatment of primary biliary cholangitis: a meta-analysis. Clin Exp Med 2023; 23: 1741–1749. PubMed

Soret PA, Lam L, Carrat F, et al.. Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis. Aliment Pharmacol Ther 2021; 53: 1138–1146. PubMed

Silveira MG, Lindor KD. Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis. Expert Opin Pharmacother 2014; 15: 365–372. PubMed

Hirschfield GM, Beuers U, Kupcinskas L, et al.. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA. J Hepatol 2021; 74: 321–329. PubMed

Zhang H, Yang J, Zhu R, et al.. Combination therapy of ursodeoxycholic acid and budesonide for PBC-AIH overlap syndrome: a meta-analysis. Drug Des Devel Ther 2015; 9: 567–574. PubMed PMC

Nevens F, Trauner M, Manns MP. Primary biliary cholangitis as a roadmap for the development of novel treatments for cholestatic liver diseases. J Hepatol 2023; 78: 430–441. PubMed

Bowlus CL, Galambos MR, Aspinall RJ, et al.. A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. J Hepatol 2022; 77: 353–364. PubMed

Jones D, Boudes PF, Swain MG, et al.. Seladelpar (MBX-8025), a selective PPAR-delta agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. Lancet Gastroenterol Hepatol 2017; 2: 716–726. PubMed

Hirschfield GM, Shiffman ML, Gulamhusein A, et al.. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study. Hepatology 2023; 78: 397–415. PubMed PMC

Mayo MJ, Vierling JM, Bowlus CL, et al.. Open-label, clinical trial extension: two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis. Aliment Pharmacol Ther 2024; 59: 186–200. PubMed

Kremer AE, Mayo MJ, Hirschfield GM, et al.. Seladelpar treatment reduces interleukin-31 and pruritus in patients with primary biliary cholangitis. Hepatology 2024; 80: 27–37. PubMed PMC

Kremer AE, Mayo MJ, Hirschfield G, et al.. Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis. Liver Int 2022; 42: 112–123. PubMed

Hirschfield GM, Bowlus CL, Mayo MJ, et al.. A phase 3 trial of seladelpar in primary biliary cholangitis. N Engl J Med 2024; 390: 783–794. PubMed

Schattenberg JM, Pares A, Kowdley KV, et al.. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. J Hepatol 2021; 74: 1344–1354. PubMed

Kowdley KV, Bowlus CL, Levy C, et al.. Efficacy and safety of elafibranor in primary biliary cholangitis. N Engl J Med 2024; 390: 795–805. PubMed

Colapietro F, Gershwin ME, Lleo A. PPAR agonists for the treatment of primary biliary cholangitis: old and new tales. J Transl Autoimmun 2023; 6: 100188. PubMed PMC

Vuppalanchi R, Caldwell SH, Pyrsopoulos N, et al.. Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis. J Hepatol 2022; 76: 75–85. PubMed

Harrison SA, Neff G, Guy CD, et al.. Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis. Gastroenterology 2021; 160: 219–231.e1. PubMed

Mayo MJ, Wigg AJ, Leggett BA, et al.. NGM282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Commun 2018; 2: 1037–1050. PubMed PMC

Elbatreek MH, Mucke H, Schmidt H. NOX inhibitors: from bench to naxibs to bedside. Handb Exp Pharmacol 2021; 264: 145–168. PubMed

Thannickal VJ, Jandeleit-Dahm K, Szyndralewiez C, et al.. Pre-clinical evidence of a dual NADPH oxidase 1/4 inhibitor (setanaxib) in liver, kidney and lung fibrosis. J Cell Mol Med 2023; 27: 471–481. PubMed PMC

Jones D, Carbone M, Invernizzi P, et al.. Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial. Hepatol Commun 2023; 7: e0057. PubMed PMC

Kowdley KV, Minuk GY, Pagadala MR, et al.. The nonsteroidal farnesoid X receptor (FXR) agonist cilofexor improves liver biochemistry in patients with primary biliary cholangitis (PBC): a phase 2, randomized, placebo-controlled trial. Hepatology 2019; 70: 31A–32A.

Schramm C, Wedemeyer H, Mason A, et al.. Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis. JHEP Rep 2022; 4: 100544. PubMed PMC

Lin W, Wang JX, Liu YJ. Optimal drug regimens for improving ALP biochemical levels in patients with primary biliary cholangitis refractory to UDCA: a systematic review and Bayesian network meta-analysis. Syst Rev 2024; 13: 46. PubMed PMC

Trivedi PJ, Kumagi T, Al-Harthy N, et al.. Good maternal and fetal outcomes for pregnant women with primary biliary cirrhosis. Clin Gastroenterol Hepatol 2014; 12: 1179–1185.e1. PubMed

European Association for the Study of the Liver. EASL Clinical Practice Guidelines: liver transplantation. J Hepatol 2016; 64: 433–485. PubMed

Reig M, Forner A, Rimola J, et al.. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 2022; 76: 681–693. PubMed PMC

Montano-Loza AJ, Wasilenko S, Bintner J, et al.. Cyclosporine A protects against primary biliary cirrhosis recurrence after liver transplantation. Am J Transplant 2010; 10: 852–858. PubMed

Corpechot C, Chazouilleres O, Belnou P, et al.. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. J Hepatol 2020; 73: 559–565. PubMed